At a glance
- Originator Abbott Laboratories
- Class Antifungals
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 29 Jan 2013 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 15 Oct 1998 No development reported - Preclinical for Mycoses in USA (unspecified route)
- 21 Oct 1996 Preclinical development for Mycoses in USA (unspecified route)